Analysts Set Pulmonx Corporation (NASDAQ:LUNG) PT at $6.81

Shares of Pulmonx Corporation (NASDAQ:LUNG) have earned a consensus rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $6.8071.

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Friday, August 1st. Lake Street Capital dropped their target price on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. Stifel Nicolaus reduced their price target on shares of Pulmonx from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Piper Sandler lowered shares of Pulmonx from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $9.00 to $2.50 in a report on Thursday, July 31st. Finally, D. Boral Capital cut their target price on Pulmonx from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th.

Institutional Trading of Pulmonx

Large investors have recently modified their holdings of the company. Corton Capital Inc. bought a new position in Pulmonx in the second quarter valued at about $32,000. Perkins Capital Management Inc. increased its position in shares of Pulmonx by 110.0% during the 3rd quarter. Perkins Capital Management Inc. now owns 21,000 shares of the company’s stock valued at $34,000 after purchasing an additional 11,000 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Pulmonx by 95.8% in the 3rd quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock worth $40,000 after purchasing an additional 12,166 shares during the period. R Squared Ltd purchased a new position in shares of Pulmonx in the second quarter worth approximately $41,000. Finally, Bank of Montreal Can bought a new stake in Pulmonx during the second quarter valued at approximately $53,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Up 1.0%

Shares of NASDAQ:LUNG opened at $1.94 on Friday. The company has a current ratio of 5.35, a quick ratio of 4.63 and a debt-to-equity ratio of 0.54. The stock has a fifty day simple moving average of $1.71 and a two-hundred day simple moving average of $2.42. Pulmonx has a 12-month low of $1.47 and a 12-month high of $9.37. The stock has a market capitalization of $79.06 million, a price-to-earnings ratio of -1.36 and a beta of 0.44.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.